Dr. John Leonard on Treatment Options for Relapsed Follicular Lymphoma

John Leonard, MD
Published: Sunday, Mar 20, 2016



John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses treatment considerations for patients with follicular lymphoma.

Current treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard. There is also data that shows that idelalisib, a P13-kinase inhibitor, can work in rituximab-refractory patients, says Leonard. R-CHOP is another options as well as radioimmunotherapy and stem-cell transplant.

Several clinical are also investigating new agents in relapsed follicular lymphoma. These include the AUGMENT study, a double-blind randomized, parallel group study that is evaluating the efficacy and safety of lenalidomide in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

<<< View more from the 2016 Congress on Hematologic Malignancies



John Leonard, MD, medical oncology, at Weill Cornell Medicine and NewYorkPresbyterian Hospital, discusses treatment considerations for patients with follicular lymphoma.

Current treatment options include rituximab and bendamustine, which have been around for sometime, as well as newer agents like obinutuzumab, says Leonard. There is also data that shows that idelalisib, a P13-kinase inhibitor, can work in rituximab-refractory patients, says Leonard. R-CHOP is another options as well as radioimmunotherapy and stem-cell transplant.

Several clinical are also investigating new agents in relapsed follicular lymphoma. These include the AUGMENT study, a double-blind randomized, parallel group study that is evaluating the efficacy and safety of lenalidomide in combination with rituximab in patients with relapsed or refractory follicular lymphoma.

<<< View more from the 2016 Congress on Hematologic Malignancies




View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Medical Crossfire®: Key Questions for the Use of Immunotherapy Throughout the Disease Continuum for NSCLC in an Era of Rapid DevelopmentSep 29, 20181.5
Provider and Caregiver Connection™: Addressing Patient Concerns While Managing GlioblastomaSep 29, 20182.0
Publication Bottom Border
Border Publication
x